Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
arcticnovartis

  • If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹
  • Recommendation based on data showing Cosentyx doubled sustained remission rates and delivered steroid sparing effects vs placebo; safety was consistent with established Cosentyx profile²
  • Despite being a common inflammatory rheumatic disease in people over 50, there are limited advanced treatments for PMR; extended use of steroids is asso
/by

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
arcticnovartis

  • If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹
  • Recommendation based on data showing Cosentyx doubled sustained remission rates and delivered steroid sparing effects vs placebo; safety was consistent with established Cosentyx profile²
  • Despite being a common inflammatory rheumatic disease in people over 50, there are limited advanced treatments for PMR; extended use of steroids is asso
/by

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
arcticnovartis

  • If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹
  • Recommendation based on data showing Cosentyx doubled sustained remission rates and delivered steroid sparing effects vs placebo; safety was consistent with established Cosentyx profile²
  • Despite being a common inflammatory rheumatic disease in people over 50, there are limited advanced treatments for PMR; extended use of steroids is asso
/by

American Chemical Society honors Novartis researchers

American Chemical Society honors Novartis researchers
halesmi2

/by

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR
   

/by

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR
   

/by